1 2 3 4 5 6	KAMALA D. HARRIS Attorney General of California JOSHUA A. ROOM Supervising Deputy Attorney General ROSAILDA PEREZ Deputy Attorney General State Bar No. 284646 455 Golden Gate Avenue, Suite 11000 San Francisco, CA 94102-7004 Telephone: (415) 703-1618 Facsimile: (415) 703-5480 Attorneys for Complainant	
7	BEFOR	F. THE
8	BOARD OF P DEPARTMENT OF C	HARMACY
9	STATE OF C	
10	In the Matter of the Accusation Against:	Case No. 5207
11	NORTH BAY CUSTOM CARE	
12	PHARMACY	ACCUSATION
13	ROBERT KONG, SEC/TRES/CFO CAROLYN KONG, SHAREHOLDER	ACCUBATION
14	1460 N. Camino Alto, Ste. 101	
15	Vallejo, CA 94589-2567	
16	Pharmacy License No. PHY 49934	
. 17	and	
18		
19	NANCY KONG CHAO 23 Railroad Avenue #366 Danville, CA 94526	
20	Pharmacist License No. RPH 48087	
21 22	Respondents.	
23	Complainant alleges:	
24	PART	TIES
25	1. Virginia Herold (Complainant) brings	this Accusation solely in her official capacity as
26	the Executive Officer of the Board of Pharmacy (E	Board), Department of Consumer Affairs.
27	2. On or about June 5, 2009, the Board of	of Pharmacy issued Original Pharmacy Permit
28	Number PHY 49934 to North Bay Custom Care F	harmacy dba North Bay Custom Care
	1	
		Accusation

.

		1
1	Pharmacy, Nancy Kong Chao, PRES/PIC, Robert Kong, SEC/TRES/CFO (Respondent	
2	Pharmacy). The Original Pharmacy Permit was in full force and effect at all times relevant to the	
3	charges brought herein. It expired on June 1, 2014 and was cancelled on July 22, 2014.	
4	3. On or about August 10, 1995, the Board of Pharmacy issued Pharmacist License No.	
5	RPH 48087 to Nancy Kong Chao (Respondent Pharmacist). The Pharmacist License was in full	
6	force and effect at all times relevant to the charges brought herein and will expire on November	
7	30, 2016, unless renewed, and for all time periods relevant to the charges herein, Respondent	
8	Pharmacist served and/or was reflected in Board records as the Pharmacist in Charge (PIC) for	
9	Respondent North Bay.	
10	JURISDICTION	
11	4. This Accusation is brought before the Board under the authority of the following laws.	
12	All section references are to the Business and Professions Code unless otherwise indicated.	
13	5. Code section 4300 provides that every license issued by the Board may be suspended	
14	or revoked.	
15	6. Code section 4300.1 states:	
16	"The expiration, cancellation, forfeiture, or suspension of a board-issued license by operation	
17	of law or by order or decision of the board or a court of law, the placement of a license on a	
18	retired status, or the voluntary surrender of a license by a licensee shall not deprive the board of	
19	jurisdiction to commence or proceed with any investigation of, or action or disciplinary proceeding	
20	against, the licensee or to render a decision suspending or revoking the license."	
21	STATUTORY PROVISIONS	
22	7. Code section 4081 states:	
23	"(a) All records of manufacture and of sale, acquisition, receipt, shipment, or disposition of	
24	dangerous drugs or dangerous devices shall be at all times during business hours open to	
25	inspection by authorized officers of the law, and shall be preserved for at least three years from the	
26	date of making. A current inventory shall be kept by every manufacturer, wholesaler, third-party	
27	logistics provider, pharmacy, veterinary food-animal drug retailer, physician, dentist, podiatrist,	
28	veterinarian, laboratory, clinic, hospital, institution, or establishment holding a currently valid and	
ŀ	2	Ì

.

Accusation

1	unrevoked certificate, license, permit, registration, or exemption under Division 2 (commencing
2	with Section 1200) of the Health and Safety Code or under Part 4 (commencing with Section
3	16000) of Division 9 of the Welfare and Institutions Code who maintains a stock of dangerous
4	drugs or dangerous devices.
5	U 11 
6	8. Code section 4105 states:
7	"(a) All records or other documentation of the acquisition and disposition of dangerous
8	drugs and dangerous devices by any entity licensed by the board shall be retained on the licensed
9	premises in a readily retrievable form.
10	11 11 •••
11	9. Code section 4160 states:
12	"(a) A person shall not act as a wholesaler or third-party logistics provider of any dangerous
13	drug or dangerous device unless he or she has obtained a license from the board.
14	it ji
15	10. Code section 4301 states:
16	"The board shall take action against any holder of a license who is guilty of unprofessional
17	conduct or whose license has been procured by fraud or misrepresentation or issued by mistake.
18	Unprofessional conduct shall include, but is not limited to, any of the following:
19	11
20	"(f) The commission of any act involving moral turpitude, dishonesty, fraud, deceit, or
21	corruption, whether the act is committed in the course of relations as a licensee or otherwise, and
22	whether the act is a felony or misdemeanor or not.
23	"(g) Knowingly making or signing any certificate or other document that falsely represents
24	the existence or nonexistence of a state of facts.
25	9
26	"(o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting the
27	violation of or conspiring to violate any provision or term of this chapter or of the applicable
28	
	3
	Accusation

1	federal and state laws and regulations governing pharmacy, including regulations established by the
2	board or by any other state or federal regulatory agency.
3	"
4	"(q) Engaging in any conduct that subverts or attempts to subvert an investigation of the
5	board.
6	л., л 
7	11. Code section 4342 states:
8	"(a) The board may institute any action or actions as may be provided by law and that, in its
9	discretion, are necessary, to prevent the sale of pharmaceutical preparations and drugs that do not
10	conform to the standard and tests as to quality and strength, provided in the latest edition of the
11	United States Pharmacopoeia or the National Formulary, or that violate any provision of the
12	Sherman Food, Drug, and Cosmetic Law (Part 5 (commencing with Section 109875) of Division
13	104 of the Health and Safety Code).
14	n
15	12. Health and Safety Code section 11165 provides, in pertinent part:
16	u
17	"(d) For each prescription for a Schedule II, Schedule III, or Schedule IV controlled
18	substance, as defined in the controlled substances schedules in federal law and regulations,
19	specifically Sections 1308.12, 1308.13, and 1308.14, respectively, of Title 21 of the Code of
20	Federal Regulations, the dispensing pharmacy, clinic, or other dispenser shall report the following
21	information to the Department of Justice as soon as reasonably possible, but not more than seven
22	days after the date a controlled substance is dispensed, in a format specified by the Department of
23	Justice:
24	
25	"(10) Date of dispensing of the prescription.
26	и.,,н
27	///
28	
	4 Accusation
ļ	II Accusation

Ę

1	13. California Code of Regulations, Title 16, section 1707.2, provides, in pertinent part:	
2	и	
3	"(b)(1) In addition to the obligation to consult set forth in subsection (a), a pharmacist shall	
4	provide oral consultation to his or her patient or the patient's agent in any care setting in which the	
5	patient or agent is present:	
6	"(A) whenever the prescription drug has not previously been dispensed to a patient; or	
7	"(B) whenever a prescription drug not previously dispensed to a patient in the same dosage	
8	form, strength or with the same written directions, is dispensed by the pharmacy.	
9	"(2) When the patient or agent is not present (including but not limited to a prescription drug	
10	that was shipped by mail) a pharmacy shall ensure that the patient receives written notice:	
11	"(A) of his or her right to request consultation; and	
12	"(B) a telephone number from which the patient may obtain oral consultation from a	
13	pharmacist who has ready access to the patient's record.	
14	n 11 	
15	14. California Code of Regulations, Title 16, section 1707.5, provides, in pertinent part:	
16	"(a) Labels on drug containers dispensed to patients in California shall conform to the	
17	following format:	
18	"(1) Each of the following items, and only these four items, shall be clustered into one area	
19	of the label that comprises at least 50 percent of the label. Each item shall be printed in at least a	
20	12-point sans serif typeface, and listed in the following order:	
21	"(A) Name of the patient	
22	"(B) Name of the drug and strength of the drug. For the purposes of this section, "name of	
23	, the drug" means either the manufacturer's trade name of the drug, or the generic name and the	
24	name of the manufacturer.	
25	"(C) The directions for the use of the drug.	
26	"(D) The condition or purpose for which the drug was prescribed if the condition or purpose	
27	is indicated on the prescription.	
28	n	
	5	
	Accusation	

1	15. California Code of Regulations, Title 16, section 1711, provides, in pertinent part:
2	"
3	"(d) Each pharmacy shall use the findings of its quality assurance program to develop
4	pharmacy systems and workflow processes designed to prevent medication errors. An
5	investigation of each medication error shall commence as soon as is reasonably possible, but no
6	later than 2 business days from the date the medication error is discovered. All medication errors
7	discovered shall be subject to a quality assurance review.
8	"(e) The primary purpose of the quality assurance review shall be to advance error
9	prevention by analyzing, individually and collectively, investigative and other pertinent data
10	collected in response to a medication error to assess the cause and any contributing factors such as
11	system or process failures. A record of the quality assurance review shall be immediately
12	retrievable in the pharmacy. The record shall contain at least the following:
13	"1. the date, location, and participants in the quality assurance review;
14	"2. the pertinent data and other information relating to the medication error(s) reviewed and
15	documentation of any patient contact required by subdivision (c);
16	"3. the findings and determinations generated by the quality assurance review; and,
17	"4. recommend changes to pharmacy policy, procedure, systems, or processes, if any.
18	"The pharmacy shall inform pharmacy personnel of changes to pharmacy policy, procedure,
19	systems, or processes made as a result of recommendations generated in the quality assurance
20	program.
21	n
22	16. California Code of Regulations, Title 16, section 1714, provides, in pertinent part:
23	n
24	"(b) Each pharmacy licensed by the board shall maintain its facilities, space, fixtures, and
25	equipment so that drugs are safely and properly prepared, maintained, secured and distributed. The
26	pharmacy shall be of sufficient size and unobstructed area to accommodate the safe practice of
27	pharmacy.
28	""
	6 Accusation
	Accusation

1	COST RECOVERY
2	17. Code section 125.3 states, in pertinent part, that the Board may request the
3	administrative law judge to direct a licentiate found to have committed a violation or violations of
4	the licensing act to pay a sum not to exceed the reasonable costs of the investigation and
5	enforcement of the case.
6	FACTS
7	18. On or about August 6, 2013 and August 29, 2013, two Board Inspectors inspected
8	Respondent Pharmacy after receiving a complaint. They were met and assisted by Respondent
9	Pharmacist. During the course of the inspections, the Inspectors discovered the following:
10	a. Respondents failed to reverse billing claims for prescriptions that were never
11	dispensed to patients;
12	b. Respondents misrepresented the drug manufacturer used (to fill prescriptions) to
13	insurance providers;
14	c. Respondents misrepresented prescription fill dates;
15	d. Respondents misrepresented dispensing dates of prescriptions to CURES;
16	e. Respondents accepted returned medications from patients for destruction;
17	f. Respondents did not refer patient L.W. <sup>1</sup> for a new medication consultation;
18	g. Respondents did not ensure patients received written notification of their right to
19	request a consultation and a telephone number to obtain the consultation;
20	h. Respondents had expired medication in the pharmacy's drug inventory;
21	i. Respondents did not have patient-centered labeling on bubble packed medications;
22	j. Respondents did not have a written policy or procedure to assist patients with
23	limited English proficiency;
24	k. Respondents failed to report and investigate medication errors related to short-
25	counted prescriptions;
26	I. Respondent's pharmacy dispensing area was cluttered and disorganized.
27	
28	<sup>1</sup> Patient name has been withheld to maintain confidentiality.
	. 7
	Accusation

19. Between approximately December 2013 and July 2014, a Board Inspector investigated
an additional complaint and discovered the following:
a. Respondents failed to maintain current drug inventory;
b. Respondents failed to maintain records of acquisition and disposition on a licensed
premise;
c. Respondents knowingly signed and filed a Discontinuation of Business form that
contained false statements; and
d. Respondents subverted the Board's investigation.
FIRST CAUSE FOR DISCIPLINE
(Act Involving Moral Turpitude, Dishonesty, Fraud, Deceit, or Corruption)
20. Respondents are subject to discipline under Code section 4301, subdivisions (f) and
(o), in that they were dishonest and committed fraud when they billed insurance providers for
medication that was not dispensed, as described in paragraph 18, above.
SECOND CAUSE FOR DISCIPLINE
(Knowingly Make or Sign Certificate or Document Falsely Representing Existence or
Nonexistence of a State of Facts)
21. Respondents are subject to disciplinary action under Code section 4301, subdivisions
(g) and (o), in that they knowingly made misrepresentations when they billed insurance providers
for the medications they did not dispense as described in paragraph 18, above.
THIRD CAUSE FOR DISCIPLINE
(Knowingly Make or Sign Certificate or Document Falsely Representing Existence or
Nonexistence of a State of Facts)
22. Respondents are subject to disciplinary action under Code section 4301, subdivision
(g) and (o), in that they knowingly falsified records indicating when a prescription was dispensed,
as described in paragraph 18, above.
///
///
8 Accusation

1	FOURTH CAUSE FOR DISCIPLINE
2	(Failure to Comply with CURES Reporting)
3	23. Respondents are subject to disciplinary action under Code section 4301, subdivisions
4	(g) and (o), and/or Health and Safety Code section 11165, subdivision (d)(10), in that they
5	misrepresented the dispensing dates of prescriptions, as described in paragraph 18, above.
6	FIFTH CAUSE FOR DISCIPLINE
7	(Acting Like Wholesaler Without License)
8	24. Respondents are subject to disciplinary action under Code sections 4301, subdivision
9	(o), and 4160, subdivision (a), in that Respondents accepted returned medication from patients for
10	destruction without having the required license to do so, as described in paragraph 18, above.
11	SIXTH CAUSE FOR DISCIPLINE
12	(Failed to Refer Patient for New Medication Consultation)
13	25. Respondents are subject to disciplinary action under Code section 4301, subdivision
14	(o), and California Code of Regulations, title 16, section 1707.2, subdivision (b)(1)(A), in that
15	Respondents failed to refer patient L.W. for a new medication consultation, as described in
16	paragraph 18, above.
17	SEVENTH CAUSE FOR DISCIPLINE
18	(Failed to Notify Patients of Right to Consultation)
19	26. Respondents are subject to disciplinary action under Code section 4301, subdivision
20	(o), and California Code of Regulations, title 16, section 1707.2, subdivision (b)(2), in that they
21	failed to ensure patients received written notification of their right to a consultation and a
22	telephone number to obtain the consultation, as described in paragraph 18, above.
23	EIGHTH CAUSE FOR DISCIPLINE
24	(Drugs Lacking Quality of Strength)
25	27. Respondents are subject to disciplinary action under Code sections 4301, subdivision
26	(o), and 4342, subdivision (a), because they had expired medications in their drug inventory, as
27	described in paragraph 18, above.
28	11/
	9 Accusation

1	NINTH CAUSE FOR DISCIPLINE	
2	(Failed to Have Patient-Centered Labels)	
3	28. Respondents are subject to disciplinary action under Code sections 4301, subdivision	
4	(o), and California Code of Regulations, title 16, section 1707.5, subdivision (a), because the	
5	pharmacy did not meet the patient-centered labeling requirements for bubble-packed medication	
6	orders, as described in paragraph 18, above.	
7	TENTH CAUSE FOR DISCIPLINE	
8	(Failed to Have Translation Services)	
9	29. Respondents are subject to disciplinary action under Code sections 4301, subdivision	
10	(o), and California Code of Regulations, title 16, section 1707.5, subdivision (d), in that they did	
11	not have written policies and procedures in place to assist patients with limited English proficiency,	
12	as described in paragraph 18, above.	
13	ELEVENTH CAUSE FOR DISCIPLINE	
14	(Failed to Investigate Medication Errors)	
15	30. Respondents are subject to disciplinary action under Code sections 4301, subdivision	
16	(o), and California Code of Regulations, title 16, section 1711 subdivision (d)(e), in that	
17	Respondents did not investigate medication errors through pharmacy's quality assurance program,	
18	as described in paragraph 18, above.	
19	TWELFTH CAUSE FOR DISCIPLINE	
20	(Failed to Keep Record Quality Assurance Review)	
21	31. Respondents are subject to disciplinary action under Code sections 4301, subdivision	
22	(o), and California Code of Regulations, title 16, section 1711 subdivision (e), in that Respondents	
23	did not keep a record of the quality assurance review related to the medication errors, as described	
24	in paragraph 18, above.	
25	///	
26		
27		
28		
	10 Accusation	

1	THIRTEENTH CAUSE FOR DISCIPLINE
2	(Disorganized Dispensing Area)
3	32. Respondents are subject to disciplinary action under Code sections 4301, subdivision
4	(o), and California Code of Regulations, title 16, section 1714 subdivision (b), in that the
5	pharmacy's dispensing area was cluttered and disorganized, as described in paragraph 18, above.
6	FOURTEENTH CAUSE FOR DISCIPLINE
7	(Failure to Maintain Current Inventory)
8	33. Respondents are subject to disciplinary action under Code section 4081, subdivision
9	(a), because they failed to maintain a current inventory of drugs in the pharmacy, as described in
. 10	paragraph 19, above.
11	FIFTEENTH CAUSE FOR DISCIPLINE
12	(Failure to Maintain Records of Acquisition and Disposition on Licensed Premises)
13	34. Respondents are subject to disciplinary action under Code section 4105, subdivision
14	(a), in that they did not keep the records of acquisition and disposition on a licensed premise
15	between approximately January 18, 2014 and January 29, 2014, as described in paragraph 19,
16	above.
17	SIXTEENTH CAUSE FOR DISCIPLINE
18	(Knowingly Sign Document with False Statements)
19	35. Respondents are subject to disciplinary action under Code section 4301, subdivision
20	(g), in that they knowingly misrepresented where the records of acquisition and disposition were
21	maintained in the Discontinuation of Business form, as described in paragraph 19, above.
22	SEVENTEENTH CAUSE FOR DISCIPLINE
23	(Subverting an Investigation)
24	36. Respondents are subject to disciplinary action under Code section 4301, subdivision
25	(q), in that they were untruthful about the location of the records of acquisition and disposition, as
26	described in paragraph 19, above.
27	///
28	///
	. 11

1	<u>PRAYER</u>
2	WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,
3	and that following the hearing, the Board of Pharmacy issue a decision:
4	1. Revoking or suspending Original Pharmacy Permit Number PHY 49934, issued to
5	North Bay Custom Care Pharmacy dba North Bay Custom Care Pharmacy, Nancy Kong Chao,
6	PRES/PIC, Robert Kong, SEC/TRES/CFO (Respondent Pharmacy);
7	2. Revoking or suspending Pharmacist License No. RPH 48087, issued to Nancy Kong
8	Chao (Respondent Pharmacist);
9	3. Ordering Respondents to pay the Board of Pharmacy the reasonable costs of the
10	investigation and enforcement of this case, pursuant to Business and Professions Code section
11	125.3;
12	4. Taking such other and further action as deemed necessary and proper.
13	
14	$\gamma$ $\beta$
15	DATED: 1/7/16 Unginia Aud
16	VIRGINIA HEROLD Executive Officer
17	Board of Pharmacy Department of Consumer Affairs
18	State of California Complainant
19	Compraintant
20	SF2014408386
21	12050471.doc
22	
23	
24	
25	
26	
27	
28	
	12 Accusation
ļ	Accusatio